These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19030237)

  • 1. Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.
    Bellavance M; Rohlicek CV; Bigras JL; Côté JM; Paquet M; Lebel MH; Mackie AS
    Paediatr Child Health; 2006 Jan; 11(1):19-23. PubMed ID: 19030237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories.
    Jalink M; Langley JM
    Paediatr Child Health; 2021; 26(2):e115-e120. PubMed ID: 36381682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
    Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF; Sondheimer HM; Tulloh RM; Harris BS; Jensen KM; Losonsky GA; Griffin MP;
    Pediatr Res; 2011 Aug; 70(2):186-91. PubMed ID: 21522037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease.
    Chiu SN; Wang CC; Lin MT; Chen CA; Lu CW; Hua YC; Wu JM; Wu MH; Wang JK
    Front Pediatr; 2021; 9():756787. PubMed ID: 35071127
    [No Abstract]   [Full Text] [Related]  

  • 8. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.
    Cohen SA; Zanni R; Cohen A; Harrington M; VanVeldhuisen P; Boron ML;
    Pediatr Cardiol; 2008 Mar; 29(2):382-7. PubMed ID: 17926087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
    Feltes TF; Cabalka AK; Meissner HC; Piazza FM; Carlin DA; Top FH; Connor EM; Sondheimer HM;
    J Pediatr; 2003 Oct; 143(4):532-40. PubMed ID: 14571236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHD and respiratory syncytial virus: global expert exchange recommendations.
    Tulloh RMR; Medrano-Lopez C; Checchia PA; Stapper C; Sumitomo N; Gorenflo M; Jung Bae E; Juanico A; Gil-Jaurena JM; Wu MH; Farha T; Dodge-Khatami A; Tsang R; Notario G; Wegzyn C
    Cardiol Young; 2017 Oct; 27(8):1504-1521. PubMed ID: 28619123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
    Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
    J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
    Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.
    Schmidt R; Majer I; García Román N; Rivas Basterra A; Grubb E; Medrano López C
    Health Econ Rev; 2017 Dec; 7(1):47. PubMed ID: 29260345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.
    Granbom E; Fernlund E; Sunnegårdh J; Lundell B; Naumburg E
    Acta Paediatr; 2014 Aug; 103(8):840-5. PubMed ID: 24724913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS; Chen X; Kumar VR
    Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
    Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.